Diligence memo · auto-generated · as of July 2, 2026
Carcinotech Ltd.
Carcinotech Ltd. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Carcinotech Ltd. operates in Biotechnology, based in SCOTLAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Carcinotech Ltd. has raised $508K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $508K on 2023-12-22.
Most recent recorded round closed around 2023-12-22.
Valuation (modeled)modeled
Provath models Carcinotech Ltd. at approximately $3.3M (range $271K–$13M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.5 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 11% of Biotechnology peers (4293 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.